“For millions living with Inflammatory Bowel Diseases (IBD), such as Crohn’s disease and ulcerative colitis (UC), every flare is a painful reminder of how little control they have over their lives. Flare-ups are unpredictable, debilitating, and costly,” said NimBio. The company has identified a clear challenge: a lack of time and actionable alerts for chronic inflammatory conditions.
“But early detection changes everything: If we could spot inflammation earlier, we could reduce flare-related hospitalizations by up to 50%, saving an estimated $5 billion annually, even with conservative assumptions,” the company added.
NimBio has developed a non-invasive Inflammometer™ technology that can be part of everyday devices like smartwatches or fitness bands. With AI-powered, non-invasive technology, it can detect the early signs of inflammation in real time before a flare begins.
Inflammatory Bowel Diseases (IBD) strike without warning — at home, at work, in the middle of your life. Flares force emergency care, disrupt daily life, and drain quality of life. IBD leads to hundreds of thousands of hospitalizations each year — not because the disease is untreatable, but because we still can’t see the flare coming.
And the economic cost is just as serious: over €5 billion is spent every year in Europe alone, and nearly $30 billion in the US, much of it on hospitalizations and emergency care that could be prevented.
Despite advances in treatment, we still can’t predict when a flare will happen — and that’s the missing piece. Early flare detection is crucial for optimal treatment and results in improved disease control, reduced complication rates, and costs.
Keep reading at calcalistech.com.
NimBio Co-founder and Chief Medical Officer is Technion Prof. Emeritus Yehuda Chowers.
